PSA Total with Free PSA and Percent Free PSA Ratio Test

The PSA Total with Free PSA and Percent Free PSA Ratio test is a blood test that measures three related values: total prostate-specific antigen, free prostate-specific antigen and the percentage of total PSA circulating in the free form. PSA is a protein produced mainly by cells of the prostate gland. A small amount normally enters the bloodstream, where it can be measured using a laboratory immunoassay.

Total PSA represents both PSA attached to blood proteins and PSA circulating freely. Free PSA measures only the unbound portion. Percent free PSA is generally calculated by dividing free PSA by total PSA and multiplying the result by 100. Evaluating these measurements together may provide more information than total PSA alone, particularly when a total PSA result falls within an intermediate or borderline range.

An increased total PSA does not automatically indicate prostate cancer. Benign prostate enlargement, prostatitis, urinary infection, recent prostate manipulation and several other factors can increase PSA. Conversely, a PSA result within a laboratory reference interval cannot completely exclude prostate cancer. The report must therefore be interpreted by a qualified healthcare professional alongside age, symptoms, medical history, examination findings, previous PSA results and other investigations.

Why Is This PSA Profile Performed?

This profile may be requested to support the assessment of prostate health, investigate an increased or borderline total PSA result, estimate the relative likelihood of prostate cancer, or help determine whether additional evaluation may be appropriate. It may also be used in selected patients who have urinary symptoms, prostate enlargement, a family history of prostate cancer, an abnormal digital rectal examination or another recognised risk factor.

Percent free PSA can be especially informative when total PSA is in a diagnostic grey zone. In general, a lower percentage of free PSA may be associated with a higher likelihood of prostate cancer, while a higher percentage may be more commonly associated with benign prostate conditions. This relationship is not absolute. The result cannot independently diagnose cancer or determine whether a biopsy is necessary.

PSA screening has possible benefits and limitations. It may help identify some prostate cancers before symptoms develop, but it can also detect slow-growing cancers that might never cause significant illness. An increased result may lead to repeat testing, imaging or biopsy, even when cancer is not present. The decision to undergo PSA testing should be made after discussing individual risk, age, general health and personal preferences with a healthcare professional.

What Does the Test Measure?

Total PSA measures the overall concentration of prostate-specific antigen in the blood, including both protein-bound and unbound forms. Free PSA measures the portion that is not attached to other proteins. The percent free PSA ratio expresses free PSA as a percentage of the total PSA concentration.

The calculation is commonly expressed as: free PSA divided by total PSA, multiplied by 100. For example, if free PSA is 1 ng/mL and total PSA is 5 ng/mL, the percent free PSA is 20%. The laboratory may calculate and report this value automatically. Calculation and reporting policies may vary when total PSA is outside the range in which percent free PSA has established clinical usefulness.

The test is performed using a serum sample collected from a vein. Laboratories may use different analytical platforms, reagents and calibration systems. Results obtained using different methods may not be directly interchangeable. When PSA is being monitored over time, using the same laboratory and method can improve comparability.

Who May Need This Test?

A healthcare professional may recommend this profile for a patient with a borderline or moderately increased total PSA result, an enlarged prostate, urinary symptoms, suspected prostate inflammation or an individual risk that requires further assessment. Symptoms may include difficulty starting urination, a weak urine stream, frequent urination, urgency, waking repeatedly at night to urinate, discomfort during urination or a feeling that the bladder has not emptied completely.

Many prostate conditions, including early prostate cancer, may produce no symptoms. For this reason, PSA testing may sometimes be considered as part of an informed screening decision. The appropriate age and frequency of testing vary according to individual risk and professional guidance. People with a strong family history or other recognised risk factors may be advised to discuss screening earlier.

This profile is not intended as a universal test for every patient. Free PSA and percent free PSA may provide limited additional information when total PSA is very low or clearly high. The treating clinician will decide whether this combined profile, a repeat total PSA, imaging, urine testing, prostate examination or another investigation is appropriate.

Sample Requirements and Test Preparation

A venous blood sample is required. The sample is generally collected into a serum tube and processed according to the laboratory's handling requirements. Fasting is usually not required specifically for this PSA profile. If other blood tests are being performed at the same time, separate fasting instructions may apply.

Patients should inform the healthcare professional about urinary infections, fever, prostatitis, recent urinary retention, catheterisation, cystoscopy, prostate biopsy, prostate surgery and any recent procedure involving the urinary tract or prostate. These conditions or procedures may temporarily increase PSA and affect interpretation. The clinician may advise postponing testing until an appropriate interval has passed.

Ejaculation and vigorous activities that place pressure on the prostate, including prolonged cycling, may temporarily influence PSA in some individuals. Patients should follow the preparation instructions supplied by their doctor or laboratory. A digital rectal examination usually has a limited effect, but collecting the blood sample before prostate manipulation may be preferred when both are planned.

Medicines must be reported accurately. Finasteride and dutasteride, which may be prescribed for benign prostate enlargement or hair loss, can reduce measured PSA levels. Testosterone treatment and other medicines may also influence prostate assessment. Patients should not stop any prescribed medicine without instructions from the treating doctor.

Understanding Total PSA Results

Total PSA is generally reported in nanograms per millilitre. There is no single value that definitively separates prostate cancer from benign conditions. PSA commonly increases with age and prostate size, and laboratories or clinicians may apply age-related reference guidance. A result above the stated reference interval requires clinical assessment but does not by itself confirm cancer.

Benign prostatic hyperplasia is a common noncancerous enlargement of the prostate and can increase total PSA. Prostatitis, urinary tract infection, urinary retention, ejaculation, prostate procedures and biological or analytical variation can also affect the result. A clinician may recommend repeating the test after a suitable interval when a temporary cause is suspected.

Changes over time may be considered along with the current result. However, PSA velocity or the rate of increase should not be used independently to diagnose prostate cancer. Previous results are most helpful when testing conditions and laboratory methods are reasonably consistent.

Understanding Free PSA and Percent Free PSA

PSA circulates in both free and protein-bound forms. Benign prostate conditions may be associated with a greater proportion of free PSA, whereas prostate cancer may be associated with a smaller free proportion. For this reason, percent free PSA may help refine risk assessment when total PSA is moderately increased.

A lower percent free PSA generally corresponds to a higher estimated probability of prostate cancer, while a higher percentage generally corresponds to a lower probability. However, cutoff values and risk estimates vary by laboratory method, age, total PSA range and clinical population. The reference or interpretation table printed on the laboratory report should be used rather than an unrelated internet range.

Percent free PSA is a risk-assessment aid and not a cancer diagnosis. A low percentage can occur without cancer, and a higher percentage cannot completely exclude cancer. The clinician may integrate the result with age, family history, ethnicity, prostate volume, digital rectal examination, previous biopsy history, multiparametric MRI findings and validated risk calculators.

What Can Affect the Accuracy of the Result?

• Prostatitis, urinary tract infection or inflammation of the prostate.
• Recent urinary retention, catheterisation or urinary-tract procedure.
• Recent prostate biopsy, prostate surgery or significant prostate manipulation.
• Ejaculation or vigorous cycling shortly before sample collection.
• Medicines such as finasteride or dutasteride that can lower PSA.
• Differences between laboratory analysers, assays and calibration methods.
• Improper sample handling, delayed processing or unsuitable storage.
• Natural biological variation between samples collected on different days.

If a result is unexpected or inconsistent with the clinical situation, the healthcare professional may recommend repeating the test under standardised conditions. Decisions about MRI, biopsy or treatment should not be based on one isolated laboratory value.

Possible Follow-Up After the Test

Follow-up depends on the complete clinical picture. A clinician may recommend a repeat PSA test, urine analysis, treatment of infection, digital rectal examination, urology consultation, prostate imaging, multiparametric MRI, another biomarker test or prostate biopsy. Not every increased PSA result requires an immediate biopsy.

A prostate biopsy is the investigation used to confirm or exclude cancer when clinically indicated, but it carries potential risks such as bleeding, infection, blood in urine or semen and temporary difficulty urinating. Percent free PSA may contribute to the decision-making process, but it does not replace professional evaluation or diagnostic procedures.

If prostate cancer has already been diagnosed or treated, the clinician will select the appropriate PSA test for monitoring. A total-and-free PSA profile is not always the preferred test after prostate removal or during treatment. Ultrasensitive PSA or serial total PSA testing may be more appropriate in certain settings.

Benefits and Limitations of the Test

The principal benefit of this profile is that it provides additional information beyond total PSA alone. It may improve risk assessment in selected patients with intermediate total PSA values and may help guide discussions about further investigation. It is a simple blood test and does not involve radiation.

Its limitations are equally important. PSA is prostate-specific but not cancer-specific. The test cannot identify the exact cause of an abnormal result, locate a prostate lesion, determine tumour aggressiveness or provide a definitive diagnosis. Results may be affected by benign disease, medication, recent activity and laboratory methodology.

PSA-based screening can produce false-positive and false-negative results. It can also contribute to overdiagnosis of slow-growing cancer and expose some patients to investigations or treatments they might not otherwise need. Shared decision-making with a healthcare professional is therefore recommended.

When Should Medical Advice Be Sought?

Patients should consult a healthcare professional if they experience persistent urinary difficulty, blood in urine or semen, pelvic discomfort, unexplained weight loss, persistent back or bone pain, or another concerning symptom. These symptoms have many possible causes and do not necessarily indicate prostate cancer, but they require proper assessment.

Urgent medical attention may be necessary if a person cannot pass urine, develops severe pain, has fever with urinary symptoms or becomes acutely unwell. A PSA blood test should not delay emergency evaluation or treatment.

Booking and Laboratory Information

The listed price for the PSA Total with Free PSA and Percent Free PSA Ratio test is ₹1350. Before sample collection, confirm current pricing, laboratory availability, preparation instructions and expected reporting time. The displayed price may cover laboratory analysis only and may not include consultation, imaging, medicines or additional procedures.

Bring previous PSA reports and provide accurate information about age, symptoms, medicines, infections and recent prostate-related procedures. Results should be reviewed by a qualified doctor or urologist. Do not make treatment decisions or assume that an abnormal PSA result means cancer without appropriate clinical evaluation and confirmatory testing.